OBJECTIVE:Plasma high-density lipoprotein (HDL) cholesterol levels are inversely correlated with the risk of developing coronary heart disease. Hormonal replacement therapy (HRT) affects plasma HDL cholesterol levels, with estrogen increasing HDL cholesterol levels and progestins blunting this effect. This study was designed to assess the mechanism responsible for these effects. MATERIALS AND METHODS:HDL apolipoprotein A-I (apoA-I) kinetics were studied in 8 healthy postmenopausal women participating in a double-blind, randomized, crossover study comprising 3 phases: placebo, conjugated equine estrogen (CEE) (0.625 mg/d), and CEE plus medroxyprogesterone acetate (MPA) (2.5 mg/d). Compared with placebo, treatment with CEE resulted in an increase in apoA-I pool size (+20%, P<0.01) because of a significant increase in apoA-I production rate (+47%, P<0.05) and no significant changes in apoA-I fractional catabolic rate. Compared with the CEE alone phase, treatment with the CEE plus MPA resulted in an 8% (P<0.02) reduction in apoA-I pool size and a significant reduction in apoA-I production rate (-13%, P<0.04), without changes in apoA-I fractional catabolic rate. CONCLUSIONS:Postmenopausal estrogen replacement increases apoA-I levels and production rate. When progestin is added to estrogen, it opposes these effects by reducing the production of apoA-I.
RCT Entities:
OBJECTIVE: Plasma high-density lipoprotein (HDL) cholesterol levels are inversely correlated with the risk of developing coronary heart disease. Hormonal replacement therapy (HRT) affects plasma HDL cholesterol levels, with estrogen increasing HDL cholesterol levels and progestins blunting this effect. This study was designed to assess the mechanism responsible for these effects. MATERIALS AND METHODS: HDL apolipoprotein A-I (apoA-I) kinetics were studied in 8 healthy postmenopausal women participating in a double-blind, randomized, crossover study comprising 3 phases: placebo, conjugated equine estrogen (CEE) (0.625 mg/d), and CEE plus medroxyprogesterone acetate (MPA) (2.5 mg/d). Compared with placebo, treatment with CEE resulted in an increase in apoA-I pool size (+20%, P<0.01) because of a significant increase in apoA-I production rate (+47%, P<0.05) and no significant changes in apoA-I fractional catabolic rate. Compared with the CEE alone phase, treatment with the CEE plus MPA resulted in an 8% (P<0.02) reduction in apoA-I pool size and a significant reduction in apoA-I production rate (-13%, P<0.04), without changes in apoA-I fractional catabolic rate. CONCLUSIONS: Postmenopausal estrogen replacement increases apoA-I levels and production rate. When progestin is added to estrogen, it opposes these effects by reducing the production of apoA-I.
Authors: K K Koh; R Mincemoyer; M N Bui; G Csako; F Pucino; V Guetta; M Waclawiw; R O Cannon Journal: N Engl J Med Date: 1997-03-06 Impact factor: 91.245
Authors: N Duverger; H Kruth; F Emmanuel; J M Caillaud; C Viglietta; G Castro; A Tailleux; C Fievet; J C Fruchart; L M Houdebine; P Denefle Journal: Circulation Date: 1996-08-15 Impact factor: 29.690
Authors: J S Millar; A H Lichtenstein; M Cuchel; G G Dolnikowski; D L Hachey; J S Cohn; E J Schaefer Journal: J Lipid Res Date: 1995-06 Impact factor: 5.922
Authors: Stela Z Berisha; Greg Brubaker; Takhar Kasumov; Kimberly T Hung; Patricia M DiBello; Ying Huang; Ling Li; Belinda Willard; Katherine A Pollard; Laura E Nagy; Stanley L Hazen; Jonathan D Smith Journal: J Lipid Res Date: 2015-01-05 Impact factor: 5.922
Authors: Francine K Welty; Alice H Lichtenstein; Stefania Lamon-Fava; Ernst J Schaefer; Julian B Marsh Journal: Metabolism Date: 2007-07 Impact factor: 8.694
Authors: Stefania Lamon-Fava; Margaret R Diffenderfer; P Hugh R Barrett; Aaron Buchsbaum; Mawuli Nyaku; Katalin V Horvath; Bela F Asztalos; Seiko Otokozawa; Masumi Ai; Nirupa R Matthan; Alice H Lichtenstein; Gregory G Dolnikowski; Ernst J Schaefer Journal: Arterioscler Thromb Vasc Biol Date: 2008-06-19 Impact factor: 8.311
Authors: Stefania Lamon-Fava; Bela F Asztalos; Timothy D Howard; David M Reboussin; Katalin V Horvath; Ernst J Schaefer; David M Herrington Journal: Clin Endocrinol (Oxf) Date: 2009-05-29 Impact factor: 3.478
Authors: Stefania Lamon-Fava; David M Herrington; David M Reboussin; Michelle Sherman; Katalin Horvath; Ernst J Schaefer; Bela F Asztalos Journal: Atherosclerosis Date: 2008-12-24 Impact factor: 5.162
Authors: Tomas Vaisar; Jennifer L Gordon; Jake Wimberger; Jay W Heinecke; Alan L Hinderliter; David R Rubinow; Susan S Girdler; Katya B Rubinow Journal: J Clin Lipidol Date: 2020-11-24 Impact factor: 4.766
Authors: Ruixin Hao; Maria Bondesson; Amar V Singh; Anne Riu; Catherine W McCollum; Thomas B Knudsen; Daniel A Gorelick; Jan-Åke Gustafsson Journal: PLoS One Date: 2013-11-06 Impact factor: 3.240